文献速递青光眼

重复小梁切除术的结局:长期随访

Outcome of repeat trabeculectomies: long-term follow-up.
PubMed 文献 · Br J Ophthalmol · 2017-01-30

该研究前瞻性评估了2000年10月至2012年12月在同一机构连续进行的独立部位重复丝裂霉素C(MMC)辅助小梁切除术的远期结局,共纳入56例患者56眼,平均随访6.3±3.4年。60个月随访时,在≤21 mmHg目标下完全成功率为56.1%、条件成功率为75.6%;平均眼压从术前29.1±6.0 mmHg降至12.6±4.7 mmHg;局部用药需求从人均2.9种降至0.5种,68.3%无需用药。作者认为,根据个体风险调整抗代谢药物的安全重复小梁切除术技术可在中长期获得改善的结果。

要点

  • 60个月随访时,≤21 mmHg目标下完全成功率56.1%、条件成功率75.6%。
  • 平均眼压从术前29.1±6.0 mmHg降至60个月时12.6±4.7 mmHg。
  • 局部用药从人均2.9种降至0.5种,68.3%的患者无需用药。

核心结论

  • 根据个体风险调整抗代谢药物的安全重复小梁切除术技术可在中长期获得改善的结果。

研究设计与样本

  • 前瞻性评估2000年10月至2012年12月在同一机构连续进行的独立部位重复MMC辅助小梁切除术。
  • 共纳入56例患者56眼,平均随访6.3±3.4年。
  • 37%的队列既往接受过辅助性小梁切除术。

主要发现

  • 60个月随访时,≤21 mmHg目标下完全成功率为56.1%、条件成功率为75.6%。
  • 60个月随访时,≤17 mmHg目标下完全成功率为53.7%、条件成功率为73.2%。
  • 60个月随访时,≤14 mmHg目标下完全成功率为51.2%、条件成功率为61.0%。
  • 平均术前眼压为29.1±6.0 mmHg,60个月随访时平均眼压为12.6±4.7 mmHg。
  • 局部用药需求从人均2.9种降至0.5种,68.3%的患者无需用药。

关键数值与推荐

  • 完全成功与条件成功(即使用或不使用青光眼药物)基于三个眼压控制水平定义:≤21、≤17和≤14 mmHg,且不伴低眼压或再次手术。
  • 60个月随访时,≤21 mmHg目标下完全成功率56.1%、条件成功率75.6%。
  • 60个月随访时,≤17 mmHg目标下完全成功率53.7%、条件成功率73.2%。
  • 60个月随访时,≤14 mmHg目标下完全成功率51.2%、条件成功率61.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To assess medium-term to long-term outcomes of a cohort of repeat trabeculectomy augmented with mitomycin C (MMC). METHODS: A prospective evaluation of consecutive separate site repeat MMC-augmented trabeculectomies undertaken at a single institution between October 2000 and December 2012. Information regarding visual acuity (VA), intraocular pressure (IOP), visual field progression, postoperative interventions, surgery complications and success of surgery are presented.Complete and qualified (ie, with or without glaucoma medication) success rates were presented on the basis of three levels of IOP control: ≤21, ≤17 and ≤14 mm Hg without hypotony or reoperation. RESULTS: Fifty-six eyes of 56 patients were evaluated. Thirty-seven per cent of the cohort had a previously augmented trabeculectomy. Mean follow-up was 6.3±3.4 years. At 60-month follow-up, 56.1% of patients achieved complete success and 75.6% achieved qualified success at the ≤21 mm Hg target. Complete and qualified success rates were 53.7% and 73.2%, respectively at the ≤17 mm Hg target and 51.2% and 61.0%, respectively at the ≤14 mm Hg target. Mean preoperative IOP was 29.1±6.0 mm Hg. At the 60-month follow-up visit the mean IOP was 12.6±4.7 mm Hg. Requirement for topical medications dropped from a mean of 2.9 to 0.5 per patient. No medications were required in 68.3%. CONCLUSIONS: Safe repeat trabeculectomy technique with antimetabolite titrated against the individual patients risk profile can result in improved results in the medium-term to long-term.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Una I, Rotchford AP, King AJ, et al. Outcome of repeat trabeculectomies: long-term follow-up. Br J Ophthalmol. 2017. PMID: 28137824. doi:10.1136/bjophthalmol-2016-309318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。